Join us during the SNMMI conference to explore our latest developments and unswerving commitment to advancing nuclear medicine. Learn about Isotopia’s Isoprotrace® kit, a European-approved 68Ga PSMA-11 labeling kit. Our commitment to weekly manufacturing and distribution of non-carrier-added and carrier-added (n.c.a & c.a) #Lu177 underscores our promise to provide reliable, high-quality nuclear medicine solutions. And finally, our new #production site in the USA signifies our ongoing commitment to enhancing operational capabilities and ensuring prompt global delivery. Visit our booth to learn more about how these developments benefit you! https://lnkd.in/diNabNM7 #radiopharmaceuticals #nuclearmedicine #molecularimaging #radionuclidetherapy #radiationtherapy #oncologytrials #theranostics #pharmaceutical #cancertreatment #prostatecancer #pharmaindustry #clinicaltrials #SNMMI24
Isotopia Molecular Imaging ltd’s Post
More Relevant Posts
-
Radiopharmaceutical clinical trials come with a host of specific challenges, including a complex regulatory landscape, a time-consuming site qualification process, and logistical issues involved with managing nuclear material. Learn more about the key risk factors here: https://bit.ly/49s9jRs
-
Radiopharmaceutical clinical trials come with a host of specific challenges, including a complex regulatory landscape, a time-consuming site qualification process, and logistical issues involved with managing nuclear material. Learn more about the key risk factors here: https://bit.ly/49s9jRs
Operationalizing Radiopharmaceutical Clinical Trials: Opportunities and Challenges - PSI CRO
https://psi-cro.com
-
Senior Director @ PSI CRO AG | Global Late Phase Studies Oncology, Hemato-Oncology, IPF, Haemophilia, radiopharmaceuticals, IBD, MS, anti-infectives, anti-fungals. Long-standing member of PCMG Assembly Steering Committee
Learn more about the key risk factors in operationalizing radiopharmaceutical clinical trials #radiopharmaceuticals #theranostics #PSICRO #clinicaltrials
Radiopharmaceutical clinical trials come with a host of specific challenges, including a complex regulatory landscape, a time-consuming site qualification process, and logistical issues involved with managing nuclear material. Learn more about the key risk factors here: https://bit.ly/49s9jRs
Operationalizing Radiopharmaceutical Clinical Trials: Opportunities and Challenges - PSI CRO
https://psi-cro.com
-
Turning the Tide – A Critical Call for Unlocking Nuclear Medicine Potential in Europe In the context of the revision of the EU Pharmaceutical Legislation, it is with great regret that the EANM and Nuclear Medicine Europe (NMEU) note that the recommendations of their joint proposals were omitted from the final position of the European Parliament. Our main concern is that this oversight risks hindering the regulatory framework for #radiopharmaceuticals, potentially impeding Europe's advancement in this crucial field. Now that the focus shifts to the Council of the EU, the EANM and NMEU urge policymakers to reconsider and prioritise developments in radiopharmaceuticals. ➡ Read our full joint statement to learn more about this pressing issue: https://lnkd.in/gY627MHs
-
-
📢 Exciting Update for Oncology Pharmacy Professionals! 📢 Dive into the latest chapter of the **Egyptian Guide for Oncology Pharmacy Practice, Volume II, Chapter II** - focused on **Nuclear and Radiological Safety: Principles and Practice of Nuclear Pharmacy**. Discover comprehensive insights on: ✅ Radiopharmaceutical fundamentals ✅ Essential radiation safety principles ✅ Regulatory frameworks ✅ Advanced preparation techniques ✅ Effective waste management ✅ Emergency preparedness ✅ Environmental and public safety Ensure you’re up-to-date with best practices and protocols to safeguard patients, healthcare workers, and the environment. Let's lead the way in safe and effective nuclear pharmacy practices! Stay informed, stay safe! 💊🔬🛡️ #OncologyPharmacy #NuclearPharmacy #Radiopharmaceuticals #RadiationSafety #PharmacyPractice #Healthcare #PatientSafety #PharmacyLeadership #EgyptianPharmacy
-
🚨 New article alert! 🚨 Amid the reform of the European Union Pharmaceutical Framework, the EANM has conducted significant advocacy efforts to bring nuclear medicine to the attention of EU decision-makers. Our latest article published in the European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI) highlights how critical changes in the EU Pharmaceutical Framework impact the field of nuclear medicine, driving innovation and patient care in the EU. 🇪🇺 Many thanks to Marianne Patt, Clemens Decristoforo, Michel Koole, Wim Oyen and Oliver Kiß, members of the EANM Policy & Regulatory Affairs Committee (PRAC), and Amélie de Martini, Head of EU Affairs, for their hard work! Read the full article here: https://lnkd.in/d9Uc8QXe #EUAffairs #PharmaceuticalFramework #PatientCare
The revision of the pharmaceutical legislation — it is time to act for nuclear medicine in Europe - European Journal of Nuclear Medicine and Molecular Imaging
link.springer.com
-
There has been much excitement in the radiopharmaceutical industry recently, which has led some to wonder about the unique challenges of introducing a pharmaceutical agent. One of the biggest challenges is the supply chain. Radioactive isotopes must be produced in specialized nuclear research reactors or generators and then transported to a production facility, where they are combined with a cancer-targeting chemical molecule. The resulting product is tested, packaged, shipped to clinics, and infused into patients. All of these steps must be done quickly and precisely since the radioactive isotopes used for therapy decay within days. The recent review by Hooijman et al. systematically explores these considerations and challenges, using Actinium-225 as an example. It may be an opportunity for some of you to “dust off” your undergraduate chemistry. Enjoy! #teamwork #radiopharmaceuticals #RPT #theranostics Eline Hooijman Erik de Blois Society of Nuclear Medicine and Molecular Imaging (SNMMI) European Association of Nuclear Medicine (EANM) American Society for Radiation Oncology American Association of Physicists in Medicine Oncidium foundation https://lnkd.in/g2Q3Rc9m
-
Discover the Future of Radiopharmaceutical Injection Systems at the European Association of Nuclear Medicine (EANM)! Don't miss the chance to see IRIS, the Radiopharmaceutical Multidose Injector, live at booth #305! 🚀 Did you know that automated injection systems like IRIS are revolutionizing the field of PET and PET/CT? These innovative systems minimize radiation exposure for operators, ensuring their safety without compromising patient care. This compact and easy-to-handle injector automatically delivers calibrated doses to patients, eliminating direct contact and reducing the risk of exposure to extremities. Plus, its long-lasting battery ensures uninterrupted performance. ⚡️ Join us at booth #305 during #EANM2023 to witness the future of radiopharmaceutical injection systems firsthand! Don't miss this opportunity to explore the capabilities of IRIS, and schedule your personal product demo here: https://bit.ly/3P5oU11 See you in Vienna! 👋 #ComecerForRadiopharma #ComecerAtEANM #IRISInjector #PatientCare #OperatorSafety
-
-
Chair and Head of Department, Nuclear Medicine and Molecular Imaging, UMCG; President of the European Association of Nuclear Medicine (EANM)
The #EANM 8 priorities regarding the Reform of the EU Pharmaceutical Legislation, so that all EU patients have equal and timely access to high quality nuclear medicine services.
❓ Do you wonder what is the nuclear medicine community’s view on the Reform of the EU Pharmaceutical Legislation? How can EU Member States ensure that all EU patients have equal and timely access to high quality nuclear medicine services? The #EANM has identified 8 priorities to address these questions: 1️⃣ A supportive regulatory framework is crucial for the field of #NuclearMedicine. The EANM calls for a reduction in regulatory burden for small-scale production, improved security of supply for #radiopharmaceuticals, and a concerted action to support and train healthcare professionals. 2️⃣ The EANM encourages health authorities to invest in in-house production services, including compounding services and the preparation of radiopharmaceuticals. 3️⃣ Small-scale in-house preparation of radiopharmaceuticals deserves strong support across the EU. The EANM advocates for a specific regulatory approach to address the differences between commercial and non-commercial production, ensuring safe and effective practices. 4️⃣ To combat radionuclide shortages, the EANM emphasises the need for improved information exchange between authorities and supply chain actors. 5️⃣ The discrepancy between the EU Pharmaceutical Legislation and #Euratom radiation protection rules is causing uncertainties and liability issues. The EANM calls for the reconciliation of medicinal product and radioprotection regulations to facilitate the market access of radiopharmaceuticals. 6️⃣ With significant advancements in the field of #NuclearMedicine since 2000, it is necessary to update definitions of radiopharmaceuticals, kits, and generators. Keeping these definitions aligned with current practices will ensure the availability of novel radiopharmaceuticals. 7️⃣ The EANM highlights the need for a limited demand for marketing authorisations within radiopharmacies. Strict limitations should apply to starting materials and radionuclide precursors used in kit procedures, rather than complex radiopharmaceutical preparations. 8️⃣ The current Good Manufacturing Practice (GMP) rules present challenges for compliance and hinder innovation in clinical settings. The EANM advocates for a relaxation of GMP requirements for investigational medicinal products, including in-house diagnostic radiopharmaceuticals. In the coming months, the EANM will continue its advocacy efforts to ensure that the voice of the #NucMed community is well represented within the discussions on the Reform of the EU Pharmaceutical Legislation. Feel free to reach out to [email protected] if you got any questions, and stay tuned for more updates on our efforts to shape the future of #NucMed and radiopharmaceuticals! 🔬 #EANM #NuclearMedicine #EUPharmaLaw #Radiopharmaceuticals #RegulatoryFramework #PatientCare #Innovation #Healthcare
-
-
PanMediso Spotlight｜ The Nuclear Medicine Industry’s Dilemma (1)BMS Suspended Phase-III Clinic for Its Nuclear Drug Product At the beginning of June, BMS announced to suspend the Phase-III clinic of its nuclear drug product due to the shortage of isotope supply. This issue has also long plagued nuclear drug giant Novartis. (2)Telix Withdrew IPO June 5th, Telix announced to withdraw IPO with a proposed price of $11.87 and plans to raise about $200 million. However, only half a month later, Telix canceled the IPO plan, the reason is that the company has enough cash, the IPO is not for fund-raising, and low pricing may harm the interests of existing shareholders. To addressing the supply of isotopes is key to navigating the dilemma for the growth of radio-pharmaceuticals.. Headquartered in the Hetao Shenzhen-HK Science and Technology Innovation Cooperation Zone, PanMediso Holdings is committed to building a global ecosystem of industry, academia, research, diagnosis & treatment for nuclear medicine and establishing world-class preparation & production centers of medical isotope to realize the GMP-grade production and global supply of new-type isotopes, particularly Ac-225 and Ge-68, thereby bringing new power to the development of human health. #BMS #Telix #IPO #Novartis #NuclearMedicine
-
